The FDA this week expanded its approval for Medtronic‘s (NYSE:MDT) MiniMed 670G hybrid closed-loop diabetes management device to include people ages 7 to 13 with Type I diabetes.
The system, which automatically monitors blood sugar levels and doses basal insulin accordingly, was initially approved in the U.S. for people ages 14 and older.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic’s MiniMed system wins FDA nod for pediatric indication appeared first on MassDevice.